表紙
市場調查報告書

全球基因藥理學(PGx)市場:各技術(DNA定序、微陣列、聚合酵素鏈鎖反應、電泳、質譜分析)、用途、地區(2018年∼2023年)

Pharmacogenomics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 704967
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球基因藥理學(PGx)市場:各技術(DNA定序、微陣列、聚合酵素鏈鎖反應、電泳、質譜分析)、用途、地區(2018年∼2023年) Pharmacogenomics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 115 Pages
簡介

全球基因藥理學(PGx)市場,預計從2018年到2023年的整個預測期內以約10.5%的年複合成長率發展。

本報告提供全球基因藥理學(PGx)市場調查,市場概要,各技術、用途、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 成長要素
    • 對精密醫療的關注
    • 研究開發的支出增加
    • 藥物有害反應的發生率高
    • 由於安全性及有效性提高的醫藥品開發研究的成功率上升
  • 阻礙因素
    • 影響藥物應答的遺傳基因變異的檢測困難
    • 償付制度的問題
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各技術
    • DNA定序
    • 微陣列
    • 聚合酵素鏈鎖反應
    • 電泳
    • 質譜分析
    • 其他
  • 各用途
    • 藥物研發
    • 個體化治療
    • 腫瘤
    • 疼痛管理
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 企業簡介和競爭情形

  • Abbott Laboratories, Inc.
  • Affymetrix, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.

第9章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 62781

Market Overview

The propelling factors for the growth of the pharmacogenomics market include the increased expenditure in R&D and an increase in the rate of adverse reactions, which has led to the higher adoption of pharmacogenomics in the global market. The increasing focus on precision medicine, along with the need to enhance drug safety and efficacy, is also further fuelling the growth of this market.

The increasing focus on precision medicine is expected to augment the pharmacogenomics market, as the goal of the precision medicine approach is to integrate genetic and environmental information of particular diseases and/or their responses to particular treatments. This is done to determine or assist in targeted drug therapies, as well as in treatment procedures to be adopted to minimize the side effects and improve results, which will require pharmacogenomics extensively. For instance, in the United States, in 2015, the government announced a new precision medicine initiative to accelerate progress toward individualized care that takes genetic variability into account for various chronic disorders.

Pharmacogenomics is also helpful in cancer treatment and has proved to improve the survival of patients, and at the same time, has found to reduce the unnecessary cost due to unresponsive treatment by patients. Hence, pharmacogenomics for cancer therapy has led to a number of important discoveries in the current cancer treatment, hence, driving the market growth during the forecast period.

The increasing expenditure in R&D and an increase in the rate of adverse reactions have led to the higher adoption of pharmacogenomics in the global market. Furthermore, there is a rapid increase in the number of research studies related to sequencing, especially next-generation sequencing, which is expected to increase the demand for pharmacogenomic tests in the future.

Scope of the Report

As per the scope of this report, pharmacogenomics is defined as the branch of biotechnology where genomic information is used to study the effect of drugs on an individual, thus, providing accurate insights in making clinical decisions and further determining the most effective way of treatment by varying the dosages of drugs. The field of pharmacogenomics is predicted to treat a wide range of health problems, including cardiovascular diseases, Alzheimer'a disease, cancer, HIV/AIDS, and asthma, in the near future.

Key Market Trends

Drug Discovery is the Segment under Application that is Expected to Grow the Fastest during the Forecast Period

Pharmacogenomics is one of the major emerging trends in the field of medical science, which greatly influences the drug development process. With the use of pharmacogenomics, target identification by drugs has become relatively easy, which ensures much higher chances of success for the approval of drugs. In addition, out of 500 genes, only 50 disease genes have drug availability in the market today. This emphasizes the market opportunity in the future for different manufacturers to concentrate on drug discovery using pharmacogenomics.

Pharmacogenomics has also found applications in the treatment of cancer patients, by anticipating the possible differences in drug response, resistance, efficacy, and toxicity of the chemotherapeutic and targeted immune biologic agents. Therefore, pharmacogenomics for cancer therapy has led to a number of important discoveries in the current cancer treatment, which has helped in the growth of the oncology segment of the market studied.

North America holds the Largest Share of the Market and is Expected to Follow the Same Trend over the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period, due to the presence of high per capita healthcare expenditure, coupled with high patient awareness levels, and the high prevalence of target diseases. Moreover, the increasing preference for personalized treatment, along with its high adoption rate, is further contributing to the growth of the market.

Competitive Landscape

The large interest of researchers and investment in the safety and efficiency of drugs by companies are one the major factors responsible for the growth of the market. The government is also involved in funding companies that work to develop bioinformatics technology for precision medicine research applications.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Focus on Precision Medicine
    • 4.2.2 Increasing Expenditure in R&D
    • 4.2.3 High Rate of Adverse Drug Reaction
    • 4.2.4 Enhancement of Drug Safety and Efficiency to Increase Success Rates in Pharmaceutical R&D
  • 4.3 Market Restraints
    • 4.3.1 Difficulties in Detecting Gene Variation that Affect Drug Response
    • 4.3.2 Reimbursement Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 DNA Sequencing
    • 5.1.2 Microarray
    • 5.1.3 Polymerase Chain Reaction
    • 5.1.4 Electrophoresis
    • 5.1.5 Mass Spectrometry
    • 5.1.6 Other Technologies
  • 5.2 By Application
    • 5.2.1 Drug Discovery
    • 5.2.2 Neurology
    • 5.2.3 Oncology
    • 5.2.4 Pain Management
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories Inc.
    • 6.1.2 Biomerieux
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bayer AG
    • 6.1.5 Becton, Dickinson and Company
    • 6.1.6 Bio-Rad Laboratories Inc.
    • 6.1.7 F. Hoffmann-La Roche Ltd
    • 6.1.8 Illumina Inc.
    • 6.1.9 Qiagen
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top